Clinical trial · Interventional
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase I Study of Imatinib (Gleevec) in Combination With Irinotecan and Cisplatin in Extensive Stage Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining imatinib mesylate with irinotecan and cisplatin in treating patients who have extensive-stage small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| imatinib mesylate | Drug | Imatinib Mesylate | ALIAS |
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed small cell lung cancer * Extensive stage disease * Measurable or evaluable indicator lesion * No symptomatic or uncontrolled brain or leptomeningeal involvement PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 70-100% Life expectancy * Not specified Hematopoietic * WBC at least 4,000/mm3 * Platelet count at least 160,000/mm3 * Hemoglobin at least 10 g/dL Hepatic * Bilirubin no greater than 1 mg/dL * AST no greater than 2.5 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 5 times ULN Renal * Creatinine less than 1.5 mg/dL OR * Creatinine clearance at least 50 mL/min Cardiovascular * No symptomatic congestive heart failure * No unstable angina pectoris * No uncontrolled cardiac arrhythmia Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for 3 months after study * No other active cancer except previously treated carcinoma in situ, non -melanoma skin cancer, or stage I prostate cancer * No ongoing or active infection * No psychiatric illness or social situation that would preclude study * No other concurrent uncontrolled illness PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy except for non-cancer conditions (e.g., low-dose methotrexate for rheumatoid arthritis) Endocrine therapy * Not specified Radiotherapy * At least 2 weeks since prior radiotherapy to major bone marrow-containing areas Surgery * Not specified Other * No concurrent warfarin for therapeutic anticoagulation * Low-molecular weight heparin or heparin allowed
References
Publications (0)
Data not yet available